Development of a second-generation antiandrogen for treatment of advanced prostate cancer.

Tran, Chris, Ouk, Samedy, Clegg, Nicola J., Chen, Yu, Watson, Philip A., Arora, Vivek, Wongvipat, John, Smith-Jones, Peter M., Yoo, Dongwon, Kwon, Andrew, Wasielewska, Teresa, Welsbie, Derek, Chen, Charlie Degui, Higano, Celestia S., Beer, Tomasz M., Hung, David T., Scher, Howard I., Jung, Michael E., Sawyers, Charles L.·2009·Science

DOI 10.1126/science.1168175

Cited by (1,000)

Items 301–400 of 1,000

Rational optimization of a transcription factor activation domain inhibitor
Basu, Shaon, Martínez-Cristóbal, Paula, Frigolé-Vivas, Marta, Pesarrodona, Mireia, Lewis, Michael, Szulc, Elzbieta, Bañuelos, C. Adriana, Sánchez-Zarzalejo, Carolina, Bielskutė, Stasė, Zhu, Jiaqi et al. · 2023 · Nature Structural & Molecular Biology
Combination Therapy with a Second-Generation Androgen Receptor Antagonist and a Metastasis Vaccine Improves Survival in a Spontaneous Prostate Cancer Model
Andressa Ardiani, Benedetto Farsaci, Connie Jo Rogers, Andy Protter, Zhimin Guo, Thomas H. King, David Apelian, James W. Hodge · 2013 · Clinical Cancer Research
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance
Shipra Shukla, Joanna Cyrta, Devan A. Murphy, Edward G. Walczak, Leili Ran, Praveen Kumar Agrawal, Yuanyuan Xie, Yuedan Chen, Shangqian Wang, Yu Zhan et al. · 2017 · Cancer Cell
Microbiota-derived bile acids antagonize the host androgen receptor and drive anti-tumor immunity
Wen‐Bing Jin, Leyi Xiao, Mingeum Jeong, Seong-Ji Han, Wen Zhang, Hiroshi Yano, Huiqing Shi, Mohammad Arifuzzaman, Mengze Lyu, Daoming Wang et al. · 2025 · Cell
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
Orazio Caffo, Ugo De Giorgi, Lucia Fratino, Daniele Alesini, Vittorina Zagonel, Gaetano Facchini, Donatello Gasparro, Cinzia Ortega, Marcello Tucci, Francesco Verderame et al. · 2014 · European Urology
Androgen hormone action in prostatic carcinogenesis: stromal androgen receptors mediate prostate cancer progression, malignant transformation and metastasis
Emily A. Ricke, Karin Williams, Yi‐Fen Lee, Suzana S. Couto, Yuzhuo Z. Wang, Simon W. Hayward, Gerald R. Cunha, William A. Ricke · 2012 · Carcinogenesis
Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism
Supriya Shah, Whitney J. Carriveau, Jinyang Li, Sydney L. Campbell, Piotr K. Kopinski, Hee‐Woong Lim, Natalie A. Daurio, Sophie Trefely, Kyoung‐Jae Won, Douglas C. Wallace et al. · 2016 · Oncotarget
The Role of Androgen Receptor Signaling in Ovarian Cancer
Taichi Mizushima, Hiroshi Miyamoto · 2019 · Cells
Triple negative breast cancer: special histological types and emerging therapeutic methods
Lu Cao, Yun Niu · 2020 · Cancer Biology and Medicine
Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Keiichiro Mori, Hadi Mostafaei, Benjamin Pradère, Reza Sari Motlagh, Fahad Quhal, Ekaterina Laukhtina, Victor M. Schuettfort, Mohammad M. Abufaraj, Pierre I. Karakiewicz, Takahiro Kimura et al. · 2020 · International Journal of Clinical Oncology
Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease
Rebecca Lee Smith, Moqing Liu, Tiera A. Liby, Nora Bayani, Elmar Bucher, Kami Chiotti, Daniel S. Derrick, Anne Chauchereau, Laura M. Heiser, Joshi J. Alumkal et al. · 2020 · Scientific Reports
Cross-resistance and drug sequence in prostate cancer
Stefan A.J. Buck, Stijn L.W. Koolen, Ron H.J. Mathijssen, Ronald de Wit, Robert J. van Soest · 2021 · Drug Resistance Updates
Novel targeted therapeutics for metastatic castration-resistant prostate cancer
Emmanuel S. Antonarakis, Michael Anthony Carducci, Mario A. Eisenberger · 2009 · Cancer Letters
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Suriyan Ponnusamy, Yali He, Dong‐Jin Hwang, Thirumagal Thiyagarajan, René Houtman, Vera Bocharova, Bobby G. Sumpter, Elias J. Fernandez, Daniel L. Johnson, Ziyun Du et al. · 2019 · Clinical Cancer Research
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
Kenrick Ng, Shievon Smith, Jonathan Shamash · 2020 · Oncology and Therapy
Androgen receptor: a potential therapeutic target for glioblastoma
Nomi Zalcman, Tamar Canello, Haim Ovadia, Hanna Charbit, Bracha Zelikovitch, Anat Mordechai, Yakov Fellig, Stav Rabani, Tal Shahar, Alexander Lossos et al. · 2018 · Oncotarget
Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma
Nan Zhao, Fei Wang, Shaheen Ahmed, Kan Liu, Chi Zhang, Sahara J. Cathcart, Dominick J. DiMaio, Michael Punsoni, Bingjie Guan, Ping Zhou et al. · 2021 · Frontiers in Oncology
Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer
Kanishka Sircar, Heng Huang, Limei Hu, David E. Cogdell, Jasreman Dhillon, Vassiliki Tzelepi, Eleni Efstathiou, Ismaël Hervé Koumakpayi, Fred Saad C, Dijun Luo et al. · 2012 · American Journal Of Pathology
Androgen–glucocorticoid interactions in the era of novel prostate cancer therapy
Sujata Narayanan, Sandy Srinivas, David Feldman · 2015 · Nature Reviews Urology
Switching and withdrawing hormonal agents for castration-resistant prostate cancer
David Lorente, Joaquı́n Mateo, Zafeiris Zafeiriou, Alan David Smith, Shahneen Kaur Sandhu, Roberta Ferraldeschi, Johann Sebastian De Bono · 2015 · Nature Reviews Urology
AZD3514: A Small Molecule That Modulates Androgen Receptor Signaling and Function In Vitro and In Vivo
Sarah A. Loddick, Sarah J. Ross, Andrew G. Thomason, David M. Robinson, Graeme E. Walker, Tom P. J. Dunkley, Sandra R. Brave, Nicola Broadbent, Natalie C. Stratton, Dawn Trueman et al. · 2013 · Molecular Cancer Therapeutics
Alkaline Phosphatase in Metastatic Castration-Resistant Prostate Cancer: Reassessment of an Older Biomarker
Daniel Alexander Heinrich, Øyvind Sverre Bruland, Theresa A. Guise, Hiroyoshi Suzuki, Oliver A. Sartor · 2018 · Future Oncology
Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer
McClinch, Kimberly, Avelar, Rita A., Callejas, David, Izadmehr, Sudeh, Wiredja, Danica, Perl, Abbey, Sangodkar, Jaya, Kastrinsky, David B., Schlatzer, Daniela, Cooper, Maxwell et al. · 2018 · Cancer Research
From pathogenesis to prevention of castration resistant prostate cancer
Helmut Bonkhoff, Richard R. Berges · 2009 · The Prostate
Agonist-specific Protein Interactomes of Glucocorticoid and Androgen Receptor as Revealed by Proximity Mapping
Joanna K. Lempiäinen, Einari A. Niskanen, Kaisa‐Mari Launonen, Riikka Lampinen, Helka Göös, Markku T Varjosalo, Jorma J. Palvimo · 2017 · Molecular & Cellular Proteomics
Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration–Approved Drugs
Nathan P. Coussens, John C. Braisted, Tyler Peryea, Gurusingham Sitta Sittampalam, Anton M. Simeonov, Matthew D. Hall · 2017 · Pharmacological Reviews
A Glutaminase Isoform Switch Drives Therapeutic Resistance and Disease Progression of Prostate Cancer
Lingfan Xu, Yu Yin, Yanjing Li, Xufeng Chen, Yan Chang, Hong Zhang, Juan Liu, James Beasley, Patricia McCaw, Haoyue Zhang et al. · 2020 · Proceedings of the National Academy of Sciences
Translational and clinical implications of the genetic landscape of prostate cancer
Daniel Eidelberg Spratt, Zachary Stephan Zumsteg, Felix Yi-Chung Feng, Scott A. Tomlins · 2016 · Nature Reviews Clinical Oncology
Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor
Derya Tilki, Edward M. Schaeffer, Christopher P. Evans · 2016 · European Urology Focus
New Developments in the Medical Management of Prostate Cancer
Manish Kohli, Donald J. Tindall · 2009 · Mayo Clinic Proceedings
Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer
Samanta Salvi, Valentina Casadio, Vincenza Conteduca, Cristian Lolli, Giorgia Gurioli, Filippo Martignano, Giuseppe Schepisi, Sara Testoni, Emanuela Scarpi, Dino Amadori et al. · 2016 · Oncotarget
Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer
Ritika Tiwari, Nishat Manzar, Vipul Bhatia, Anjali Yadav, Mushtaq Ahmad Nengroo, Dipak B. Datta, Shannon L. Carskadon, Nilesh Gupta, Michael Sigouros, Francesca Khani et al. · 2020 · Nature Communications
Castration-Resistant Prostate Cancer: AUA Guideline Amendment 2015
William Thomas Lowrance, Bruce J. Roth, Erin Kirkby, Mohammad Hassan Murad, Michael S. Cookson · 2015 · The Journal of Urology
Androgen metabolism in prostate cancer: from molecular mechanisms to clinical consequences
K-H Chang, Cesar Emilio Ercole, Nima Sharifi · 2014 · British Journal of Cancer
Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): Head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model
Robert D. Bruno, Tadas Sean Vasaitis, Lalji K. Gediya, Puranik Purushottamachar, Abhijit M. Godbole, Zeynep Ateş‐Alagöz, Angela M. H. Brodie, Vincent C.O. Njar · 2011 · Steroids
Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
David Ulmert, Michael J. Evans, Jason P. Holland, Samuel L. Rice, John Wongvipat, Kim S. I. Pettersson, Per-Anders Abrahamsson, Peter T. Scardino, Steven M. Larson, Hans G. Lilja et al. · 2012 · Cancer Discovery
Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer
Emmanuel S. Antonarakis, Chandtip Chandhasin, Erica Osbourne, Jun Luo, Marianne D. Sadar, Frank Perabo · 2016 · The Oncologist
Clinical utility of androgen receptor gene aberrations in circulating cell-free DNA as a biomarker for treatment of castration-resistant prostate cancer
Takayuki Sumiyoshi, Kei Mizuno, Toshinari Yamasaki, Yu Miyazaki, Yuki Makino, Kosuke Okasho, Xin Li, Noriaki Utsunomiya, Takayuki Goto, Takashi Kobayashi et al. · 2019 · Scientific Reports
Metastatic castration‐sensitive prostate cancer: Abiraterone, docetaxel, or…
Pedro Coelho Barata, Oliver A. Sartor · 2019 · Cancer
The androgen receptor/filamin A complex as a target in prostate cancer microenvironment
Marzia Di Donato, Alice Zamagni, Giovanni Galasso, Erika Di Zazzo, Pia Giovannelli, Maria Vittoria Barone, Michele Zanoni, Roberta Gunelli, Matteo Costantini, Ferdinando Auricchio et al. · 2021 · Cell Death and Disease
Extracellular Matrix in Synthetic Hydrogel‐Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors
Matthew J. Mosquera, Sungwoong Kim, Rohan Bareja, Zhou Fang, Shuangyi Cai, Heng Pan, Muhammad Imran Asad, M. Laura Martín, Michael Sigouros, Florencia P. Madorsky Rowdo et al. · 2021 · Advanced Materials
Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
Andressa Ardiani, Sofia R. Gameiro, Anna R. Kwilas, Renee Nicole Donahue, James W. Hodge · 2014 · Oncotarget
siRNA Lipid Nanoparticle Potently Silences Clusterin and Delays Progression When Combined with Androgen Receptor Cotargeting in Enzalutamide-Resistant Prostate Cancer
Yoshiaki Yamamoto, Paulo J.C. Lin, Eliana Beraldi, Fan Zhang, Yoshihisa Kawai, Jeffrey Leong, Hidemasa Katsumi, Ladan Fazli, Robert Fraser, Pieter R. Cullis et al. · 2015 · Clinical Cancer Research
Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Nima Sharifi · 2013 · Molecular Endocrinology
Multivalent Peptidomimetic Conjugates: A Versatile Platform for Modulating Androgen Receptor Activity
Paul M. Levine, Keren Imberg-Kazdan, Michael J. Garabedian, Kent Kirshenbaum · 2012 · Journal of the American Chemical Society
Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond
Simon Linder, Henk G. van der Poel, Andries Marinus Bergman, Wilbert T. Zwart, Stefan Preković · 2018 · Endocrine Related Cancer
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial
Weijie Gu, Weiqing Han, Hong Luo, Fangjian Zhou, Dalin He, Lulin Ma, Hongqian Guo, Chang Yin Liang, Tie Chong, Jun Jiang et al. · 2022 · The Lancet Oncology
The Crucial Role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant Prostate Cancer
Zeyuan Zheng, Jinxin Li, Yankuo Liu, Zhiyuan Shi, Zuodong Xuan, Kunao Yang, Chunlan Xu, Yang Bai, Meiling Fu, Qiaohong Xiao et al. · 2022 · Cancers
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src
Xu-Bao Shi, Ai‐Hong Ma, Lingru Xue, Meimei Li, Hao Gia Nguyen, Joy C. Yang, Clifford G. Tepper, Regina F. Gandour‐Edwards, Christopher P. Evans, Hsing-Jien Kung et al. · 2015 · Cancer Research
A New Avenue toward Androgen Receptor Pan-antagonists: C2 Sterically Hindered Substitution of Hydroxy-propanamides
Andrea Guerrini, Anna Tesei, Claudia Ferroni, Giulia Paganelli, Alice Zamagni, Silvia Carloni, Marzia Di Donato, Gabriella Castoria, Carlo Leonetti, Manuela Porru et al. · 2014 · Journal of Medicinal Chemistry
Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture
Theresa Eder, Anja Weber, Hannes Neuwirt, Georg Grünbacher, Christian Ploner, Helmut Klocker, Natalie Sampson, Iris Elisabeth Eder · 2016 · International Journal of Molecular Sciences
Mechanisms and biotechnological applications of transcription factors
Hehe He, Yang Mingfei, Siyu Li, Gaoyang Zhang, Zhongyang Ding, Liang N. Zhang, Guiyang Shi, Youran Li · 2023 · Synthetic and Systems Biotechnology
Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer
Yeung Ho, Scott M. Dehm · 2017 · Endocrinology
Molecular Imaging in Cancer Drug Development
Stijn J.H. Waaijer, Iris C. Kok, Bertha Eisses, Carolina Pia Schroder, Mathilde Jalving, Adrienne H. Brouwers, Marjolijn N. Lub–de Hooge, Elisabeth G.E. de Vries · 2018 · Journal of Nuclear Medicine
Structure and Function of the Nuclear Receptor Superfamily and Current Targeted Therapies of Prostate Cancer
Baylee A. Porter, Maria Antonia Ortiz, Gennady Bratslavsky, Leszek Kotula · 2019 · Cancers
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis
Hyun Ho Han, Yan Wang, Josué Curto, Sreeharsha Gurrapu, Sara Laudato, Alekya Rumandla, Goutam Chakraborty, Xiaobo Wang, Hong Chen, Yan Jiang et al. · 2022 · Cell Reports
Targeting Alternative Sites on the Androgen Receptor to Treat Castration-Resistant Prostate Cancer
Nada Lallous, Kush Dalal, Artem R Cherkasov, Paul S. Rennie · 2013 · International Journal of Molecular Sciences
Cotargeting Androgen Receptor and Clusterin Delays Castrate-Resistant Prostate Cancer Progression by Inhibiting Adaptive Stress Response and AR Stability
Hiroaki Matsumoto, Yoshiaki Yamamoto, Masaki Shiota, Hidetoshi Kuruma, Eliana Beraldi, Hideyasu Matsuyama, Amina Zoubeidi, Martin Edwin Gleave · 2013 · Cancer Research
Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Nazanin Momeni Roudsari, Naser‐Aldin Lashgari, Saeideh Momtaz, Shaghayegh Abaft, Fatemeh Jamali, Pardis Safaiepour, Kiyana Narimisa, Gloria Jackson, Anusha Bishayee, Nima Rezaei et al. · 2021 · Pharmaceutics
Discovery of Aryloxy Tetramethylcyclobutanes as Novel Androgen Receptor Antagonists
Chuangxing Guo, Angelica Linton, Susan E. Kephart, Martha A. Ornelas, Mason Pairish, Javier González, Samantha E. Greasley, Asako Nagata, Benjamin J. Burke, Martin P. Edwards et al. · 2011 · Journal of Medicinal Chemistry
Skp2 deficiency restricts the progression and stem cell features of castration-resistant prostate cancer by destabilizing Twist
D Ruan, Jinrong He, Chien‐Feng Li, H-J Lee, J Liu, H-K Lin, Chia‐Hsin Chan · 2017 · Oncogene
Overcoming Chemotherapy Resistance in Prostate Cancer
Ravi Amrit Madan, Sumanta Kumar Pal, Oliver A. Sartor, William L. Dahut · 2011 · Clinical Cancer Research
Mini-review: Foldosome regulation of androgen receptor action in prostate cancer
Laia Querol Cano, Derek N. Lavery, Charlotte Lynne Bevan · 2013 · Molecular and Cellular Endocrinology
MUC1 oncoprotein is a druggable target in human prostate cancer cells
Maya Datt Joshi, Rehan Ahmad, Yin Li, Deepak Bushan Raina, Hasan N. Rajabi, Glenn J. Bubley, Surender M. Kharbanda, Donald W. Kufe · 2009 · Molecular Cancer Therapeutics
Elucidating the modes of action for bioactive compounds in a cell-specific manner by large-scale chemically-induced transcriptomics
M Iwata, Ryusuke Sawada, Hiroaki Iwata, Masaaki Kotera, Yoshihiro Yamanishi · 2017 · Scientific Reports
Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer
Licai He, Zhuanyun Du, Xusheng Xiong, Hua Ma, Zhenfeng Zhu, Hongwei Gao, Jiawei Cao, Tong Li, Hongzhi Li, Kaiyan Yang et al. · 2017 · Scientific Reports
Epigenetic Therapy with Panobinostat Combined with Bicalutamide Rechallenge in Castration-Resistant Prostate Cancer
Anna C. Ferrari, Joshi J. Alumkal, Mark N. Stein, Mary‐Ellen Taplin, James S. Babb, Ethan S. Barnett, Alejandro Gómez-Pinillos, Xiaomei Liu, Dirk F. Moore, Robert S. DiPaola et al. · 2018 · Clinical Cancer Research
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer
Francesca Vignani, Valentina Bertaglia, Consuelo Buttigliero, Marcello Tucci, Giorgio V. Scagliotti, Massimo Di Maïo · 2016 · Cancer Treatment Reviews
The evolving role of immune cells in prostate cancer
Chao Wang, Yan Zhang, Wei‐Qiang Gao · 2021 · Cancer Letters
Androgen receptor mutations for precision medicine in prostate cancer
Masaki Shiota, Shusuke Akamatsu, Shigehiro Tsukahara, Shohei Nagakawa, Takashi Matsumoto, Masatoshi Eto · 2022 · Endocrine Related Cancer
Enzalutamide After Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer
Sebastian Christoph Schmid, Alexander Geith, Alena Böker, Robert Tauber, Anna Katharina Seitz, Markus Antonius Kuczyk, Christoph A. J. von Klot, Jürgen E. Gschwend, Axel S. Merseburger, Margitta M. Retz · 2014 · Advances in Therapy
Targeting 5α-reductase for prostate cancer prevention and treatment
Lucas P. Nacusi, Donald J. Tindall · 2011 · Nature Reviews Urology
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
Oliver A. Sartor · 2011 · Journal of Hematology & Oncology
Progress in emerging therapies for advanced prostate cancer
Stéphane Marie. Oudard · 2012 · Cancer Treatment Reviews
Bioactive nanotherapeutic trends to combat triple negative breast cancer
Pallabita Chowdhury, Upasana Ghosh, Kamalika Samanta, Meena Jaggi, Subhash C. Chauhan, Murali Mohan Yallapu · 2021 · Bioactive Materials
Identification of a Potent Antiandrogen that Targets the BF3 Site of the Androgen Receptor and Inhibits Enzalutamide-Resistant Prostate Cancer
Ravi S. N. Munuganti, Mohamed D.H. Hassona, Eric Leblanc, Kate Frewin, Kriti Singh, Dennis Ma, Fuqiang Ban, Michael Hsing, Hans H. Adomat, Nada Lallous et al. · 2014 · Chemistry & Biology
Recent developments in antiandrogens and selective androgen receptor modulators
Bernard Haendler, Arwed Cleve · 2011 · Molecular and Cellular Endocrinology
Androgen Receptor: A Complex Therapeutic Target for Breast Cancer
Ramesh Narayanan, James T. Dalton · 2016 · Cancers
The androgen receptor regulates a druggable translational regulon in advanced prostate cancer
Yuzhen Liu, Jessie L. Horn, Kalyan Banda, Asha Z. Goodman, Yiting Lim, Sujata Jana, Sonali Arora, Alexandre A. Germanos, Lexiaochuan Wen, William R. Hardin et al. · 2019 · Science Translational Medicine
Discovering the hidden messages within cell trajectories using a deep learning approach for in vitro evaluation of cancer drug treatments
Arianna Mencattini, Davide Di Giuseppe, Maria Colomba Comes, Paola Casti, Francesca Corsi, Francesca Romana Bertani, Lina Ghibelli, Luca Businaro, C. Di Natale, Maria Carla Parrini et al. · 2020 · Scientific Reports
CircRNA-UCK2 increased TET1 inhibits proliferation and invasion of prostate cancer cells via sponge miRNA-767-5p
Zhendong Xiang, Chengdang Xu, Gang Wu, Bo Liu, Denglong Wu · 2019 · Open Medicine
Gremlin1 is a therapeutically targetable FGFR1 ligand that regulates lineage plasticity and castration resistance in prostate cancer
Chaping Cheng, Jinming Wang, Penghui Xu, Kai Zhang, Zhixiang Xin, Huifang Zhao, Zhongzhong Ji, Man Zhang, Deng Wang, Yuman He et al. · 2022 · Nature Cancer
Targeting androgen receptor degradation with PROTACs from bench to bedside
Xiaojuan Jia, Xin Han · 2022 · Biomedicine & Pharmacotherapy
Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
Alejo Rodríguez‐Vida, Simon Chowdhury, Cora Nanette Sternberg, Sarah Maria Rudman, Myria Galazi · 2015 · Drug Design Development and Therapy
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
Berkley E. Gryder, Michelle J. Akbashev, Michael Kenneth Rood, Eric D. Raftery, Warren M. Meyers, Paulette Dillard, Shafiq A. Khan, Adegboyega K. Oyelere · 2013 · ACS Chemical Biology
PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis
Hong Pu, Craig Horbinski, Patrick Joseph Hensley, Emily A. Matuszak, Timothy H. Atkinson, Natasha Kyprianou · 2014 · Carcinogenesis
Molecules targeting the androgen receptor (AR) signaling axis beyond the AR‐Ligand binding domain
N. G. R. Dayan Elshan, Matthew B. Rettig, Michael E. Jung · 2018 · Medicinal Research Reviews
The role of adrenal derived androgens in castration resistant prostate cancer
Monique Barnard, Elahe A. Mostaghel, Richard Joseph Auchus, Karl‐Heinz Storbeck · 2019 · The Journal of Steroid Biochemistry and Molecular Biology
Overview of the latest treatments for castration-resistant prostate cancer
Mohamed Bishr, Fred Saad C · 2013 · Nature Reviews Urology
Handling smart environment devices, data and services at the semantic level with the FI-WARE core platform
Fano Ramparany, Fermín Galán Márquez, Javier Soriano, Tarek Elsaleh · 2014 · IEEE International Conference on Big Data (BigData)
Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers
John W. Phillips, Yang Pan, Brandon L. Tsai, Zhijie Xie, Levon Demirdjian, Wen Xiao, Harry Taegyun Yang, Yida Zhang, Chia Ho Lin, Donghui Cheng et al. · 2020 · Proceedings of the National Academy of Sciences
A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants
Feng Sun, Inthrani Raja Indran, Zhi Wei Zhang, M.H.Eileen Tan, Yu Li, Z.L.Ryan Lim, Rui Hua, Chong Yang, F.-F. Soon, Jun Li et al. · 2015 · Carcinogenesis
Metastatic castration-resistant prostate cancer (CRPC): preclinical and clinical evidence for the sequential use of novel therapeutics
Deborah Mukherji, Aurelius Gabriel Omlin, Carmel Jo Pezaro, Ali I. Shamseddine, Johann Sebastian De Bono · 2014 · Cancer and Metastasis Reviews
Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53- deficiency-driven castration-resistant prostate cancer
Lei Wang, Ji Wang, Hua Xiong, Fengxia Wu, Tian Lan, Yingjie Zhang, Xiaolan Guo, Huanan Wang, Mohammad Saleem, Cheng Jiang et al. · 2016 · EBioMedicine
Combination of palbociclib with enzalutamide shows in vitro activity in RB proficient and androgen receptor positive triple negative breast cancer cells
Chun‐Yu Liu, Ka-Yi Lau, Chia‐Chi Hsu, Ji-Lin Chen, Chia-Han Lee, Tzu‐Ting Huang, Yi‐Ting Chen, Chun-Teng Huang, Po‐Han Lin, Ling‐Ming Tseng · 2017 · PLoS ONE
Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers
Michael A. Ulm, Arvind V. Ramesh, Keely May McNamara, Suriyan Ponnusamy, Hironobu Sasano, Ramesh Narayanan · 2019 · Endocrine Connections
Crystal structures of AKR1C3 containing an N-(aryl)amino-benzoate inhibitor and a bifunctional AKR1C3 inhibitor and androgen receptor antagonist. Therapeutic leads for castrate resistant prostate cancer
Mo Chen, Adegoke O. Adeniji, Barry M. Twenter, Jeffrey D. Winkler, David W. Christianson, T.M. Penning · 2012 · Bioorganic & Medicinal Chemistry Letters
Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity
Hiromitsu Kawata, Nobuyuki Ishikura, Miho Watanabe, Ayako Nishimoto-Kakiuchi, Toshiaki Tsunenari, Yuko Aoki · 2010 · The Prostate
Second-Generation Androgen Receptor Antagonists as Hormonal Therapeutics for Three Forms of Prostate Cancer
Pravien S. Rajaram, Alyssa Rivera, Kevin Muthima, Nicholas Olveda, Hubert Muchalski, Qiao‐Hong Chen · 2020 · Molecules
Tracking the expression of therapeutic protein targets in rare cells by antibody-mediated nanoparticle labelling and magnetic sorting
Mahmoud Labib, Zongjie Wang, Sharif Uddin Ahmed, Reza M. Mohamadi, Bill T. V. Duong, Brenda J. Green, Edward Hartley Sargent, Shana O. Kelley · 2020 · Nature Biomedical Engineering